EC approves Celltrion’s Omlyclo for allergic conditions
The EC has approved Celltrion’s Omlyclo, an omalizumab biosimilar for reference product Xolair to treat allergic conditions.
The EC has approved Celltrion’s Omlyclo, an omalizumab biosimilar for reference product Xolair to treat allergic conditions.
What's Your Reaction?
